BOT — Botanix Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- AU$763.40m
- AU$715.83m
- AU$0.60m
Annual income statement for Botanix Pharmaceuticals, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
C2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.171 | 0.104 | 0.037 | 0.169 | 0.602 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 16.7 | 3.38 | 13.2 | 9.23 | 14.6 |
| Operating Profit | -16.5 | -3.28 | -13.1 | -9.06 | -14 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -16.7 | -3.33 | -13.2 | -9.15 | -13.9 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -16.7 | -3.33 | -13.2 | -9.15 | -13.9 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -16.7 | -3.33 | -13.2 | -9.15 | -13.9 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -16.7 | -3.33 | -13.2 | -9.15 | -13.9 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.018 | -0.003 | -0.014 | -0.008 | -0.008 |